Kuno van der Post Ph.D
OmniComm Systems, Inc.
Download Product Brochure
Download Integration Datasheet
Download Case Study
See an Article About this Integration
Integrated Partnership with PharmaPros Dataflow Manager Enables New Functionality
Fort Lauderdale, FL, June 25, 2012 - OmniComm Systems, Inc. (OTC: OMCM.OB), one of the fastest growing companies in the Electronic Data Capture (EDC) marketplace, today announced a new level of integration with PharmaPros that provides OmniComm customers with a solution offering next-generation CTMS capabilities for mid-sized organizations interested in a flexible, SaaS solution for clinical trials management. This new integrated solution provides capabilities for Site Management & Monitoring, Budget Tracking & Management, eTMF / Document Tracking, Metrics Portal & Real-time Reporting. With access to these new tools, OmniComm customers can manage their clinical trial information in a more automated and scalable way. Connecting Trial Master EDC directly to Dataflow Manager through the OmniConnect web-based API eliminates the administrative burden of redundant data entry and reconciliation for clinical Sponsor and CRO organizations across a wide range of eClinical products, reducing trial costs, and providing significant workflow efficiencies.
"We are extremely pleased that OmniComm is now bundling Dataflow Manager's unique study management capabilities with their TrialMaster EDC product," said Brion Regan, Head of Strategic Development, PharmaPros. "We've already seen the benefits within our shared customer base, and have been impressed. OmniComm has proven to be a strong technology partner, with the ability to rapidly address the needs of their customers with value-driven solutions."
This integrated partnership enables OmniComm customers to add Dataflow Manager to their TrialMaster solution on an as-needed or per-trial basis. This flexibility gives customers the ability to quickly scale up or down, based on the needs of the trial, without costly and time-consuming implementations required by traditional CTMS solutions.
“We are excited about this new partnership and the benefits this marriage of EDC and CTMS will provide to our customers,” said Stephen Johnson, President and COO of OmniComm. “This integrated partnership and solution is just one more example of how OmniComm is continuing to help our customers connect data across the eClinical spectrum.”
OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.
PharmaPros Corporation (www.PharmaPros.com) is a technology solutions provider for the life sciences industry. The company’s innovative approach and deep industry expertise have resulted in innovative solutions that are redefining clinical trials technology. PharmaPros is a leader in the emerging generation of cloud-based solutions for clinical trials. The company was formed in 1996, and is located in Cambridge, MA.
Safe Harbor Disclaimer
Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.